Mednet Logo
HomeRadiation OncologyQuestion

For a patient with terminal ileal Crohns disease who requires chemoRT for distal rectal cancer, can mercaptopurine (6MP) be continued during that phase of treatment?

1 Answers
Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

6MP is an antimetabolite that was not developed as a radiosensitizer. So at the right dose it is probably a selective radiosensitizer similar to 5FU. There are no data reported with radiation and 6MP, so this statement is just deductive reasoning. The worst that can happen is an enhancement of acute...

Register or Sign In to see full answer

For a patient with terminal ileal Crohns disease who requires chemoRT for distal rectal cancer, can mercaptopurine (6MP) be continued during that phase of treatment? | Mednet